$GH
Guardant Health, Inc. Stock $gh

$gh Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000157628022000058 Filed on August 04, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$117.4M	$109.1M	$96.10M
YoY Change	23.87%	18.5%	22.16%
Cost Of Revenue	$40.50M	$36.73M	$31.98M
YoY Change	31.41%	22.72%	11.24%
Gross Profit	$76.91M	$72.42M	$64.12M
YoY Change	20.24%	16.47%	28.44%
Gross Profit Margin	65.51%	66.35%	66.72%
Selling, General & Admin	$121.5M	$117.3M	$105.7M
YoY Change	21.15%	22.05%	3.35%
% of Gross Profit	157.97%	161.96%	164.85%
Research & Development	$100.0M	$85.46M	$81.76M
YoY Change	40.93%	34.1%	47.29%
% of Gross Profit	130.05%	118.0%	127.51%
Depreciation & Amortization	$9.100M	$8.100M	$7.201M
YoY Change	82.0%	58.82%	43.73%
% of Gross Profit	11.83%	11.19%	11.23%
Operating Expenses	$221.5M	$202.7M	$187.5M
YoY Change	29.35%	26.86%	18.81%
Operating Profit	-$144.6M	-$130.3M	-$123.3M
YoY Change	34.78%	33.47%	14.35%
Interest Expense	$644.0K	$645.0K	$644.0K
YoY Change	0.0%	0.16%	-0.31%
% of Operating Profit
Other Income/Expense, Net	-$18.39M	$378.0K	-$48.00K
YoY Change	9733.69%	-255.56%	-83.45%
Pretax Income	-$161.9M	-$229.0M	-$123.3M
YoY Change	50.68%	134.88%	14.92%
Income Tax	$115.0K	$446.0K	-$24.00K
% Of Pretax Income
Net Earnings	-$162.0M	-$229.4M	-$123.2M
YoY Change	50.66%	135.13%	14.78%
Net Earnings / Revenue	-137.98%	-210.21%	-128.23%
Basic Earnings Per Share	-$1.58	-$2.25	-$1.21
Diluted Earnings Per Share	-$1.58	-$2.25	-$1.21
COMMON SHARES
Basic Shares Outstanding	102.2M shares	102.0M shares	101.9M shares
Diluted Shares Outstanding	102.3M shares	102.0M shares	101.9M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$958.0M	$853.7M	$962.3M
YoY Change	-35.53%	-52.35%	-50.41%
Cash & Equivalents	$158.3M	$215.2M	$573.6M
Short-Term Investments	$799.7M	$638.5M	$388.7M
Other Short-Term Assets	$23.57M	$28.28M	$30.07M
YoY Change	7.32%	47.03%	91.53%
Inventory	$63.05M	$59.89M	$36.61M
Prepaid Expenses
Receivables	$86.20M	$95.28M	$84.33M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.131B	$1.037B	$1.113B
YoY Change	-29.03%	-45.16%	-45.24%
LONG-TERM ASSETS
Property, Plant & Equipment	$168.0M	$163.4M	$151.3M
YoY Change	58.26%	82.05%	110.86%
Goodwill	$3.290M	$3.290M	$3.290M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$12.42M	$13.11M	$13.73M
YoY Change	-15.52%	-13.7%	-12.42%
Long-Term Investments	$156.7M	$382.6M	$588.5M
YoY Change	-37.36%	590.97%
Other Assets	$51.73M	$70.56M	$70.92M
YoY Change	-15.64%	94.47%	310.01%
Total Long-Term Assets	$570.9M	$816.6M	$1.016B
YoY Change	-9.68%	103.73%	223.98%
TOTAL ASSETS
Total Short-Term Assets	$1.131B	$1.037B	$1.113B
Total Long-Term Assets	$570.9M	$816.6M	$1.016B
Total Assets	$1.702B	$1.854B	$2.130B
YoY Change	-23.53%	-19.12%	-9.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$40.91M	$36.97M	$32.23M
YoY Change	161.01%	72.77%	44.41%
Accrued Expenses	$63.37M	$77.16M	$51.85M
YoY Change	56.56%	141.13%	87.57%
Deferred Revenue	$13.42M	$14.96M	$10.57M
YoY Change	83.45%	76.36%	26.44%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$175.1M	$167.8M	$228.8M
YoY Change	71.18%	73.64%	139.59%
LONG-TERM LIABILITIES
Long-Term Debt	$1.137B	$1.136B	$1.135B
YoY Change	0.23%	0.23%	0.23%
Other Long-Term Liabilities	$6.988M	$9.287M	$6.909M
YoY Change	104.09%	273.57%	318.47%
Total Long-Term Liabilities	$6.988M	$9.287M	$6.909M
YoY Change	104.09%	273.57%	318.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$175.1M	$167.8M	$228.8M
Total Long-Term Liabilities	$6.988M	$9.287M	$6.909M
Total Liabilities	$1.535B	$1.535B	$1.597B
YoY Change	5.38%	6.25%	10.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.522B	-$1.360B	-$1.131B
YoY Change	66.04%	68.09%	58.9%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$166.7M	$319.1M	$533.0M
YoY Change
Total Liabilities & Shareholders Equity	$1.702B	$1.854B	$2.130B
YoY Change	-23.53%	-19.12%	-9.25%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$162.0M	-$229.4M	-$123.2M
YoY Change	50.66%	135.13%	14.78%
Depreciation, Depletion And Amortization	$9.100M	$8.100M	$7.201M
YoY Change	82.0%	58.82%	43.73%
Cash From Operating Activities	-$78.16M	-$111.9M	-$28.62M
YoY Change	47.07%	78.83%	75.67%
INVESTING ACTIVITIES
Capital Expenditures	-$21.73M	-$23.03M	$22.70M
YoY Change	-1.91%	23.37%	136.8%
Acquisitions
YoY Change
Other Investing Activities	$63.00M	-$49.86M	$133.5M
YoY Change	-349.55%	-134.21%	0.04%
Cash From Investing Activities	$41.27M	-$72.89M	$110.8M
YoY Change	-187.09%	-157.37%	-10.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-19.31M	-172.1M	-$12.00K
YoY Change	247.34%	-3607.68%	-99.98%
NET CHANGE
Cash From Operating Activities	-78.16M	-111.9M	-$28.62M
Cash From Investing Activities	41.27M	-72.89M	$110.8M
Cash From Financing Activities	-19.31M	-172.1M	-$12.00K
Net Change In Cash	-56.20M	-356.9M	$81.39M
YoY Change	-47.03%	-614.45%	122.73%
FREE CASH FLOW
Cash From Operating Activities	-$78.16M	-$111.9M	-$28.62M
Capital Expenditures	-$21.73M	-$23.03M	$22.70M
Free Cash Flow	-$56.43M	-$88.90M	-$51.32M
YoY Change	82.07%	102.4%	98.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001576280
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38683
	dei	Entity Registrant Name EntityRegistrantName	GUARDANT HEALTH, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-4139254
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3100 Hanover Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Palo Alto
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94304
	dei	City Area Code CityAreaCode	855
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Local Phone Number LocalPhoneNumber	698-8887
	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value per share
	dei	Trading Symbol TradingSymbol	GH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	102220389	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	215169000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	492202000	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	638521000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	440546000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	95276000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	97652000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	59890000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	30674000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28283000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	53052000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	1037139000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1114126000	usd
CY2022Q2	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	382575000	usd
CY2021Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	698034000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	163362000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	124461000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	183703000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	189443000	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	13108000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14207000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	3290000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	3290000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	70560000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	60938000	usd
CY2022Q2	us-gaap	Assets Assets	1853737000	usd
CY2021Q4	us-gaap	Assets Assets	2204499000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	36971000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17580000	usd
CY2022Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	38672000	usd
CY2021Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	42496000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	77157000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45285000	usd
CY2022Q2	gh	Investments Payable InvestmentsPayable	0	usd
CY2021Q4	gh	Investments Payable InvestmentsPayable	78000000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	14955000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11326000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	167755000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	194687000	usd
CY2022Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1136105000	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1134821000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	221503000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	226053000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9287000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3933000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	1534650000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	1559494000	usd
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2021Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	102186856	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	102186856	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101767446	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101767446	shares
CY2022Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	usd
CY2021Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1703832000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1657593000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-24261000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4764000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1360485000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1007825000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	319087000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	645005000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1853737000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2204499000	usd
CY2022Q2	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	92062000	usd
CY2021Q2	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	72604000	usd
	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	176198000	usd
	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	136333000	usd
CY2022Q2	gh	Revenue From Development Services RevenueFromDevelopmentServices	17082000	usd
CY2021Q2	gh	Revenue From Development Services RevenueFromDevelopmentServices	19497000	usd
	gh	Revenue From Development Services RevenueFromDevelopmentServices	29045000	usd
	gh	Revenue From Development Services RevenueFromDevelopmentServices	34433000	usd
CY2022Q2	us-gaap	Revenues Revenues	109144000	usd
CY2021Q2	us-gaap	Revenues Revenues	92101000	usd
	us-gaap	Revenues Revenues	205243000	usd
	us-gaap	Revenues Revenues	170766000	usd
CY2022Q2	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	34375000	usd
CY2021Q2	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	24887000	usd
	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	65059000	usd
	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	48477000	usd
CY2022Q2	gh	Cost Of Development Services CostOfDevelopmentServices	2352000	usd
CY2021Q2	gh	Cost Of Development Services CostOfDevelopmentServices	5040000	usd
	gh	Cost Of Development Services CostOfDevelopmentServices	3649000	usd
	gh	Cost Of Development Services CostOfDevelopmentServices	10197000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	85455000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	63724000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	167212000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	119232000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	73603000	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	47716000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	138035000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	82054000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43680000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48376000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	84947000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	116311000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	239465000	usd
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	189743000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	458902000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	376271000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-130321000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-97642000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-253659000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-205505000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1387000	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1037000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2165000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2588000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	645000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	644000	usd
	us-gaap	Interest Expense InterestExpense	1289000	usd
	us-gaap	Interest Expense InterestExpense	1290000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	378000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-243000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	330000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-533000	usd
CY2022Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-99785000	usd
CY2021Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-99785000	usd
	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-228986000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-97492000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-352238000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-204740000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	446000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	422000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	193000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-229432000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-97575000	usd
	us-gaap	Profit Loss ProfitLoss	-352660000	usd
	us-gaap	Profit Loss ProfitLoss	-204933000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	2300000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-229432000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-229432000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-97575000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-97575000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-352660000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-352660000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-207233000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-207233000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.25
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.25
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.96
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.96
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.05
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102047000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102047000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101172000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101172000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101950000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101950000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101064000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101064000	shares
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-229432000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-97575000	usd
	us-gaap	Profit Loss ProfitLoss	-352660000	usd
	us-gaap	Profit Loss ProfitLoss	-204933000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4528000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-878000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-17286000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1584000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1419000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	7000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-2211000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1080000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-5947000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-871000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-19497000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2664000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-235379000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-98446000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-372157000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-207597000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	0	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest	2300000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-235379000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-98446000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-372157000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-209897000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	533040000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1194000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5742000	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1222000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25544000	usd
CY2022Q2	gh	Adjustments To Additional Paid In Capital Tender Offer Issued AdjustmentsToAdditionalPaidInCapitalTenderOfferIssued	9832000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-5947000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-229432000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	319087000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	847046000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	926000	usd
CY2021Q2	gh	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	13000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5401000	usd
CY2021Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1382000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34507000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-871000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-97575000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	788065000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	645005000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2157000	usd
	gh	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	8000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5742000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2179000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50343000	usd
	gh	Adjustments To Additional Paid In Capital Tender Offer Issued AdjustmentsToAdditionalPaidInCapitalTenderOfferIssued	9832000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-19497000	usd
	us-gaap	Profit Loss ProfitLoss	-352660000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	319087000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1298495000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5388000	usd
	gh	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	26000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5401000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	74958000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	89576000	usd
	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	-2300000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2664000	usd
	us-gaap	Profit Loss ProfitLoss	-204933000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	788065000	usd
	us-gaap	Profit Loss ProfitLoss	-352660000	usd
	us-gaap	Profit Loss ProfitLoss	-204933000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15986000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10637000	usd
	gh	Non Cash Operating Lease Costs NonCashOperatingLeaseCosts	14197000	usd
	gh	Non Cash Operating Lease Costs NonCashOperatingLeaseCosts	10839000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3805000	usd
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	875000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	50343000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	89576000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1284000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1282000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-3800000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-6528000	usd
	gh	Fair Value Adjustments Of Noncontrolling Interest Liability FairValueAdjustmentsOfNoncontrollingInterestLiability	-99785000	usd
	gh	Fair Value Adjustments Of Noncontrolling Interest Liability FairValueAdjustmentsOfNoncontrollingInterestLiability	0	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-20000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-8000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2355000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	368000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	29218000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3778000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-23670000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3036000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-4301000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4282000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	11089000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7112000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3824000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	6455000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	15159000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7304000	usd
	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-6595000	usd
	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-3033000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	5949000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-70000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-140554000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78884000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	238601000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	126163000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	335000000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	418110000	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	12750000	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	12750000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45734000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28261000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	37915000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	250936000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	35000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	91000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2158000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5388000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5742000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	5401000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2179000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	74958000	usd
	gh	Payments For Joint Venture Acquisition Financing Activities PaymentsForJointVentureAcquisitionFinancingActivities	177785000	usd
	gh	Payments For Joint Venture Acquisition Financing Activities PaymentsForJointVentureAcquisitionFinancingActivities	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	784000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-172099000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-65044000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2211000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1080000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-276949000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	105928000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	492288000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	832977000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	215339000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	938905000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4073000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	170911000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	16901000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10289000	usd
	gh	Equity Securities Fvni Incurred But Not Yet Paid EquitySecuritiesFVNIIncurredButNotYetPaid	0	usd
	gh	Equity Securities Fvni Incurred But Not Yet Paid EquitySecuritiesFVNIIncurredButNotYetPaid	587000	usd
	gh	Property Plant And Equipment Acquired Under Finance Leases PropertyPlantAndEquipmentAcquiredUnderFinanceLeases	0	usd
	gh	Property Plant And Equipment Acquired Under Finance Leases PropertyPlantAndEquipmentAcquiredUnderFinanceLeases	236000	usd
	gh	Noncash Tender Offer Issued NoncashTenderOfferIssued	9688000	usd
	gh	Noncash Tender Offer Issued NoncashTenderOfferIssued	0	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	215169000	usd
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	938590000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	170000	usd
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	315000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	215339000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	938905000	usd
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	39400000	usd
CY2021Q4	gh	Contractual Receivables After Allowance For Credit Loss Net Current ContractualReceivablesAfterAllowanceForCreditLossNetCurrent	0	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and </span></div>other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of non-marketable securities, valuation of redeemable noncontrolling interest and noncontrolling interest liability, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates. The severity of the impact on the Company's business for the remainder of calendar year 2022 and beyond will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, and the impact of any variants of the virus, the extent and severity of the impact on the Company's customers and suppliers, the continued disruption to demand for the Company's products and services, and the impact of the global business and economic environment on liquidity and the availability of capital, all of which are uncertain and cannot be predicted.
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	200000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	100000	usd
CY2022Q2	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	52200000	usd
	gh	Equity Security Fvni Impairment Or Adjustments To Carrying Value EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services, and development services and other, primarily with biopharmaceutical companies and international laboratory partners, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at net amount.</span></div>The Company is also subject to credit risk from its other receivables and other assets.
CY2020Q3	gh	Contractual Receivables Before Allowance For Credit Loss ContractualReceivablesBeforeAllowanceForCreditLoss	8000000	usd
CY2020Q3	gh	Contractual Receivables Term ContractualReceivablesTerm	P6Y
CY2020Q4	gh	Proceeds From Contractual Receivable ProceedsFromContractualReceivable	1000000	usd
CY2021Q4	gh	Proceeds From Contractual Receivable ProceedsFromContractualReceivable	1100000	usd
	gh	Contractual Receivables Credit Loss Expense Reversal Noncurrent ContractualReceivablesCreditLossExpenseReversalNoncurrent	5900000	usd
CY2022Q2	gh	Contractual Receivables Before Allowance For Credit Loss Gross Current ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent	1100000	usd
CY2021Q4	gh	Contractual Receivables Before Allowance For Credit Loss Gross Current ContractualReceivablesBeforeAllowanceForCreditLossGrossCurrent	0	usd
CY2022Q2	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	1100000	usd
CY2021Q4	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	0	usd
CY2022Q2	gh	Contractual Receivables After Allowance For Credit Loss Net Current ContractualReceivablesAfterAllowanceForCreditLossNetCurrent	0	usd
CY2022Q2	gh	Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent	4800000	usd
CY2021Q4	gh	Contractual Receivables Before Allowance For Credit Loss Gross Noncurrent ContractualReceivablesBeforeAllowanceForCreditLossGrossNoncurrent	5900000	usd
CY2022Q2	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	4800000	usd
CY2021Q4	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	5900000	usd
CY2022Q2	gh	Contractual Receivables After Allowance For Credit Loss Net Noncurrent ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent	0	usd
CY2021Q4	gh	Contractual Receivables After Allowance For Credit Loss Net Noncurrent ContractualReceivablesAfterAllowanceForCreditLossNetNoncurrent	0	usd
CY2021Q4	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	0	usd
CY2020Q4	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	0	usd
	gh	Contractual Receivables Credit Loss Reclassification Current ContractualReceivablesCreditLossReclassificationCurrent	1100000	usd
	gh	Contractual Receivables Credit Loss Reclassification Current ContractualReceivablesCreditLossReclassificationCurrent	1100000	usd
CY2022Q2	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	1100000	usd
CY2021Q2	gh	Contractual Receivables Allowance For Credit Loss Current ContractualReceivablesAllowanceForCreditLossCurrent	1100000	usd
CY2021Q4	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	5900000	usd
CY2020Q4	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	7000000	usd
	gh	Contractual Receivables Credit Loss Reclassification Noncurrent ContractualReceivablesCreditLossReclassificationNoncurrent	-1100000	usd
	gh	Contractual Receivables Credit Loss Reclassification Noncurrent ContractualReceivablesCreditLossReclassificationNoncurrent	-1100000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	5700000	usd
CY2022Q2	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	4800000	usd
CY2021Q2	gh	Contractual Receivables Allowance For Credit Loss Noncurrent ContractualReceivablesAllowanceForCreditLossNoncurrent	5900000	usd
CY2022Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	4900000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q2	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q2	gh	Post Acquisition Contingent Consideration Expense PostAcquisitionContingentConsiderationExpense	200000	usd
	gh	Post Acquisition Contingent Consideration Expense PostAcquisitionContingentConsiderationExpense	2300000	usd
CY2021Q2	gh	Post Acquisition Contingent Consideration Expense PostAcquisitionContingentConsiderationExpense	0	usd
	gh	Post Acquisition Contingent Consideration Expense PostAcquisitionContingentConsiderationExpense	0	usd
CY2022Q2	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	1600000	usd
CY2021Q2	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	9600000	usd
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	3600000	usd
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	14600000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	17300000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2300000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	11300000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5300000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	6400000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	124461000	usd
CY2021Q4	gh	Investments Payable InvestmentsPayable	78000000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	232922000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	179285000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	69560000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	54824000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	163362000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	8100000	usd
CY2021Q2	us-gaap	Depreciation Depreciation	5100000	usd
	us-gaap	Depreciation Depreciation	14800000	usd
	us-gaap	Depreciation Depreciation	9600000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	19302000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12856000	usd
CY2022Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3222000	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	4223000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	10669000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	6994000	usd
CY2022Q2	gh	Accrued Clinical Trials And Studies AccruedClinicalTrialsAndStudies	6841000	usd
CY2021Q4	gh	Accrued Clinical Trials And Studies AccruedClinicalTrialsAndStudies	3332000	usd
CY2022Q2	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	9230000	usd
CY2021Q4	gh	Estimated Litigation Liability Legal Fees Current EstimatedLitigationLiabilityLegalFeesCurrent	4166000	usd
CY2022Q2	gh	Accrued Expenses Property And Equipment Current AccruedExpensesPropertyAndEquipmentCurrent	5601000	usd
CY2021Q4	gh	Accrued Expenses Property And Equipment Current AccruedExpensesPropertyAndEquipmentCurrent	5893000	usd
CY2022Q2	gh	Tender Offer Issued Joint Venture Acquisition Current TenderOfferIssuedJointVentureAcquisitionCurrent	9248000	usd
CY2021Q4	gh	Tender Offer Issued Joint Venture Acquisition Current TenderOfferIssuedJointVentureAcquisitionCurrent	0	usd
CY2022Q2	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	3000000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10044000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7821000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	77157000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45285000	usd
CY2022Q2	gh	Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost	1166542000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	20878000	usd
CY2022Q2	gh	Cash Cash Equivalents And Debt Securities Fair Value CashCashEquivalentsAndDebtSecuritiesFairValue	1145664000	usd
CY2021Q4	gh	Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost	1499957000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3594000	usd
CY2021Q4	gh	Cash Cash Equivalents And Debt Securities Fair Value CashCashEquivalentsAndDebtSecuritiesFairValue	1496365000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18586000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5478000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13108000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	3290000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16986000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4379000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12607000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	3290000	usd
CY2022Q2	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	21876000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5478000	usd
CY2022Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	16398000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	3290000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	3290000	usd
CY2021Q4	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	21876000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4379000	usd
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	17497000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	usd
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1100000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1382000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2747000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2219000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1670000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1212000	usd
CY2022Q2	gh	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	3878000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	13108000	usd
CY2020Q4	gh	Convertible Debt Hedge Strike Price ConvertibleDebtHedgeStrikePrice	182.60
CY2020Q4	gh	Convertible Debt Hedge Share Price Premium Percentage ConvertibleDebtHedgeSharePricePremiumPercentage	0.75
CY2020Q4	us-gaap	Share Price SharePrice	104.34
CY2020Q4	gh	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Hedges AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges	90000000	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	7200000	usd
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	6900000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	14200000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	10800000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y6M
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0398
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0401
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	13643000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	30337000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	32834000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	32201000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	27703000	usd
CY2022Q2	gh	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	149645000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	286363000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	45558000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	240805000	usd
	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16682131	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13416775	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5231624	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2624974	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.17
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	193014000	usd
	gh	Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	346149	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	37.28
	gh	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Connection With The Joint Venture Acquisition Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInConnectionWithTheJointVentureAcquisitionGross	15128	shares
	gh	Share Based Compensation Arrangements By Share Based Payment Award Options Granted In Connection With The Joint Venture Acquisition Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantedInConnectionWithTheJointVentureAcquisitionWeightedAverageExercisePrice	4.90
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	156015	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.20
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	18937	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	76.21
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7369757	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2811299	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	30.99
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	66643000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2016108	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.60
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	63137000	usd
CY2022Q1	gh	Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	23.41
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	81.79
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	23.67
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	84.02
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	32700000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25544000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	34507000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50343000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	89576000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-229432000	usd
CY2021Q2	us-gaap	Profit Loss ProfitLoss	-97575000	usd
	us-gaap	Profit Loss ProfitLoss	-352660000	usd
	us-gaap	Profit Loss ProfitLoss	-204933000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
CY2021Q2	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	0	usd
	us-gaap	Net Income Loss Attributable To Redeemable Noncontrolling Interest NetIncomeLossAttributableToRedeemableNoncontrollingInterest	2300000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-229432000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-229432000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-97575000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-97575000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-352660000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-352660000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-207233000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-207233000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.25
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.25
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.96
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.96
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.46
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.05
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102047000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102047000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101172000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101172000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101950000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101950000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101064000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101064000	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15272000	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14813000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15116000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15090000	shares
CY2022Q2	us-gaap	Revenues Revenues	109144000	usd
CY2021Q2	us-gaap	Revenues Revenues	92101000	usd
	us-gaap	Revenues Revenues	205243000	usd
	us-gaap	Revenues Revenues	170766000	usd

Files In Submission

Name	View Source	Status
0001576280-22-000058-index-headers.html	Edgar Link	pending
0001576280-22-000058-index.html	Edgar Link	pending
0001576280-22-000058.txt	Edgar Link	pending
0001576280-22-000058-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gh-06302022x10qxex311.htm	Edgar Link	pending
gh-06302022x10qxex312.htm	Edgar Link	pending
gh-06302022x10qxex313.htm	Edgar Link	pending
gh-06302022x10qxex321.htm	Edgar Link	pending
gh-06302022x10qxex322.htm	Edgar Link	pending
gh-06302022x10qxex323.htm	Edgar Link	pending
gh-20220630.htm	Edgar Link	pending
gh-20220630.xsd	Edgar Link	pending
gh-20220630_cal.xml	Edgar Link	unprocessable
gh-20220630_def.xml	Edgar Link	unprocessable
gh-20220630_htm.xml	Edgar Link	completed
gh-20220630_lab.xml	Edgar Link	unprocessable
gh-20220630_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GH
Guardant Health, Inc. Stock $gh

2022 Q3 Form 10-Q Financial Statement

#000157628022000058 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH Guardant Health, Inc. Stock $gh

2022 Q3 Form 10-Q Financial Statement

#000157628022000058 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH
Guardant Health, Inc. Stock $gh